Lihui Wang

发表

Active transport of imatinib into and out of cells: implications for drug resistance.

Munir Pirmohamed, M. Pirmohamed, R. Clark, 2004, Blood.

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

R. Clark, Lihui Wang, K. Pearson, 2003, British journal of haematology.

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

R. Clark, Lihui Wang, K. Knight, 2006, Haematologica.

resistance Active transport of imatinib into and out of cells: implications for drug

M. Pirmohamed, R. Clark, Julia Thomas, 2013 .

Guidelines for the measurement of BCR‐ABL1 transcripts in chronic myeloid leukaemia

N. Cross, H. White, L. Foroni, 2011, British journal of haematology.

Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia

R. Clark, Lihui Wang, K. Pearson, 2002, British journal of haematology.

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells.

R. Clark, A. Giannoudis, Lihui Wang, 2012, Experimental hematology.

Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts

M. Pirmohamed, S. Pushpakom, R. Clark, 2019, Leukemia.

Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.

R. Clark, J. Rojas, Lihui Wang, 2010, Experimental hematology.

Chronic Myeloid LeukemiaResearch Paper

R. Clark, J. Rojas, S. Christmas, 2005 .

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.

R. Clark, J. Rojas, S. Christmas, 2005, Haematologica.

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

R. Clark, A. Giannoudis, Robert J. Harris, 2009, Haematologica.

hOCT 1 and resistance to imatinib.

M. Pirmohamed, R. Clark, B. Druker, 2005, Blood.

A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.

R. Clark, S. Lane, Lihui Wang, 2013, Leukemia research.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Brief report EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

D. Marin, J. Goldman, L. Foroni, 2010 .

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.

R. Clark, S. Christmas, Lihui Wang, 2004, Blood.

A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers

Thomas L. Dunwell, Daniel Catchpoole, L. Hesson, 2010, Molecular Cancer.

The Safety of Chemotherapy for Ovarian Malignancy during Pregnancy

Lihui Wang, Jin Peng, Xinlei Sui, 2022, Journal of clinical medicine.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

K. Rezvani, R. Clark, D. Marin, 2013, Blood.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Martin C. Müller, M. Pirmohamed, S. Pushpakom, 2013, Blood.

myeloid leukemia: implications for early intervention strategies Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

A. Mead, M. Rozman, N. Cross, 2022, Blood advances.

Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells

Lihui Wang, A. Holcroft, G. Austin, 2015, European journal of haematology.

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

H Emons, V Kairisto, S Trapmann, 2014, Leukemia.

BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.

R. Clark, J. Rojas, Lihui Wang, 2011, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Martin C. Müller, D. Colomer, J. Gabert, 2010, Blood.

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

R. Clark, D. Marin, J. Goldman, 2011 .